Impressive Revenue Growth
Total revenues for Q4 2024 were $307 million, an increase of $24 million over the prior quarter and $48 million over Q4 2023. Product revenues were $182 million, up $24 million from the previous quarter and $37 million from Q4 2023.
Return to Profitability
Omnicell reported a Q4 2024 GAAP earnings per share of $0.34, compared to a loss of $0.32 per share in Q4 2023.
Strong Bookings Performance
Full year 2024 bookings were $923 million, exceeding guidance and representing a $69 million increase compared to full year 2023.
Innovative Product Demand
Demand for XT Amplify program products and XTExtend showed solid growth, contributing to improved bookings performance.
Positive Customer Wins
Significant contracts were secured with NYC Health + Hospitals and other healthcare systems for XT automated cabinets and inventory optimization services.